Drug
Hjb647 Low Dose
Hjb647 Low Dose: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| HJB647 low dose NCT07465653 | Phase 1 | Heart Failure With Reduced Ejection Fraction |
Latest
No recent events.
Follow Hjb647 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.